Duoenda (mitoxantrone liposomal) / CSPC Pharma - LARVOL DELTA

Mitoxantrone Hydrochloride Liposome Combined with COEP (CMOEP) as First-Line Therapy for Peripheral T-Cell Lymphoma: Interim Results of the Phase II COMPASS Trial (ESMO 2026) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Phase II Clinical Study of Liposomal Mitoxantrone Combined with Azacitidine in Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma (ESMO 2026) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

RPLM-RS: Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL (clinicaltrials.gov) - P2 | N=23 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P2 trial • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Richter's Syndrome • BCL2

Liposomal-Mitoxantrone Overcomes Acquired Resistance and Enhances Venetoclax Synergy in AML-Mechanistic Insights and Preliminary Clinical Evidence. (PubMed, Int J Nanomedicine) - "Liposomal reformulation altered the therapeutic, transcriptional, and cell-death pattern of mitoxantrone in the models. These findings suggest that liposomal mitoxantrone may reduce hematologic toxicity and limit the emergence of drug resistance."

Journal • Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Transplantation

A single-arm, multicenter phase II clinical study of venetoclax combined with liposomal mitoxantrone and cytarabine as induction therapy in young patients with acute myeloid leukemia (AML) (ChiCTR) - P2 | N=32 | Recruiting | Sponsor: HenanCancerHospital; HenanCancerHospita

New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control (ASH 2025) - P=N/A | "CMG+VEN represents a more safe alternative regimen in sAML and elderly AML patients,showing higher MRD negative rate and deserving further investigation."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm

Liposomal mitoxantrone, venetoclax and azacitidine in relapsed/refractory acute myeloid leukaemia and early induction failure: a single-centre real-world study. (PubMed, Front Oncol) - "These findings suggest that MVA had clinical activity as a salvage regimen for difficult-to-treat AML, including patients with prior venetoclax failure, with expected myelosuppression and potential bridging utility before allo-HSCT. Prospective studies are needed to confirm efficacy and define patient selection."

Journal • Real-world evidence • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Thrombocytopenia • Transplantation

Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=197 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting | Trial primary completion date: Aug 2025 ➔ Aug 2027

Enrollment open • Trial primary completion date • Non-Hodgkin’s Lymphoma

SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - P2 | N=320 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML (clinicaltrials.gov) - P=N/A | N=27 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Clinical Study on the Efficacy and Safety of MVRd Regimen in the Treatment of Newly Diagnosed Multiple Myeloma with Extramedullary Disease (EMD) (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Xi'an Jiaotong University Second Affiliated Hospital; Xi'an Jiaotong University Second Affiliated Hospital

New P4 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML (clinicaltrials.gov) - P3 | N=168 | Not yet recruiting | Sponsor: Ruijin Hospital

New P3 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • BCL2

R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study. (PubMed, BMC Med) - P=N/A | "The Lipo-MIT-based R-MINE-containing regimen showed encouraging efficacy and a manageable safety profile in R/R DLBCL, warranting further validation."

Journal • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial. (PubMed, Cell Transplant) - P=N/A | "The MTBF regimen for salvage allo-HSCT in R/R AML exhibited notable anti-leukemia activity and tolerable toxicity. (NCT06385808, Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML)."

Clinical • Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Mucositis • Transplantation

GOLIDOCITINIB、MITOXANTRONE HYDROCHLORIDE LIPOSOME、CHIDAMIDE AND PREDNISONE (GO-MCP) IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA:A REAL-WORLD RETROSPECTIVE STUDY (EHA 2026) - "Of note, one PTCL patient with CNS relapse after five cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and subsequent progression on second ‑ line methotrexate/temozolomide with intrathecal therapy achieved CR on PET ‑ CT after 7 cycles of Go ‑ MCP.This result indicated promising efficency in CNS relapse patients and in mitoxantrone exposure patients.Two enrolled patients have proceeded to autologous stem cell transplantation following Go-MCP treatment, with the longest progression- free survival (PFS) reaching 190 days to date, demonstrating deep remission of Go-MCP regimen. Grade 3 infections occurred in five patients (71.4%, including three of pulmonary infection, two of skin infection, and one of abdominal infection); No hemolysis or other hematolymphatic disorders were observed. . Summary/Conclusion In conclusion, the Go ‑ MCP regimen demonstrates preliminary efficacy and a generally manageable safety profile in patients with R/R PTCL, but..."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Herpes Zoster • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Varicella Zoster

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN ADVANCED-STAGE MYCOSIS FUNGOIDES: A 26-CASE RETROSPECTIVE COHORT STUDY FROM CHINA (EHA 2026) - "Most used agents: BV (81%, 21), HDAC inhibitors (58%, 15), golidocitinib (46%, 12), liposomal mitoxantrone (31%, 8),reflecting highly individualized sequencing in real-world practice. All 3 FMF patients receiving golidocitinib remain alive and progression-free. . Summary/Conclusion This real-world cohort with extended follow-up demonstrates: 1) BV is highly active in advanced MF, with post-BV interferon maintenance offering durable disease control; 2) Post-BV options remain limited with modest efficacy; 3) Golidocitinib produced durable responses in FMF, suggesting JAK inhibition warrants prospective study in this subtype."

HEOR • Metastases • Real-world • Real-world evidence • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology • TNFRSF8

GOLIDOCITINIB AND LIPOSOMAL MITOXANTRONE FOR RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY FROM A MULTI-CENTER RETROSPECTIVE STUDY (EHA 2026) - "Summary/Conclusion The combination of golidocitinib and liposomal mitoxantrone demonstrates a manageable safety profile and promising preliminary efficacy in patients with R/R PTCL. A prospective Phase II study is ongoing to further validate these encouraging findings."

Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • ALK

BRENTUXIMAB VEDOTIN COMBINED WITH CHIDAMIDEIN AND MITOXANTRONE HYDROCHLORIDE LIPOSOME OR GOLIDOCITINIB IN RELAPSED/REFRACTORY CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA: A REAL-WORLD STUDY DESIGN (EHA 2026) - "Among these, BV, a CD30-directed ADC, combined with chidamide, an HDAC inhibitor, has been proven to have a synergistic effect and recommended in relapsed/refractory (R/R) settings. Summary/Conclusion This study is designed to provide robust evidence for the combination therapy (BV plus chidamidein and MIT-LIP or golidocitinib) in RW settings, potentially offering a valuable therapeutic strategy in patients with R/R CD30+ CTCL. The study is recruiting, with preliminary results available in subsequent reports."

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia. (PubMed, Invest New Drugs) - "The conditioning regimen was Lipo-MIT + total body irradiation/busulfan + cyclophosphamide ± cytarabine, with a median Lipo-MIT dose of 26.1 (18.5-28.9) mg/m2. Lipo-MIT conditioning shows promising efficacy/safety for allo-HSCT in extramedullary disease patients. Randomized trials are needed."

Journal • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Myelofibrosis • Oncology • Polycythemia Vera • Sarcoma • Solid Tumor • Transplantation

A NOVEL STRATEGY TO CIRCUMVENT VENETOCLAX RESISTANCE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA : UPDATED RESULTS FROM A PHASE II TRIAL (EHA 2026) - P2 | "Mitoxantrone hydrochloride liposome (Lipo-MIT), a novel anthracycline nano-drug, has shown improved pharmacokinetics and activity. We initiated the MAV regimen (Lipo-MIT, cytarabine, and VEN) for R/R AML (NCT06621212)...Common grade 3/4 non-hematological TRAEs included febrile neutropenia (40%), pulmonary infection (17.1%), and sepsis (8.6%). Summary/Conclusion The MAV regimen demonstrates promising efficacy and manageable toxicity in R/R AML, including particular potential to overcome VEN resistance in relapsed patients with prior venetoclax exposure, with the trial ongoing."

P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Respiratory Diseases • Septic Shock • Thrombocytopenia • ASXL1 • RUNX1 • SRSF2 • STAG2

REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME COMBINED WITH ETOPOSIDE, METHYLPREDNISOLONE IN THE TREATMENT OF LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (EHA 2026) - "It should be noted that cytopenia is a hallmark of active HLH, making precise attribution to therapy challenging. . Summary/Conclusion The MEP regimen showed good tolerance and clinically meaningful efficacy in the treatment of LA-HLH."

Clinical • Real-world • Real-world evidence • Cardiovascular • Diffuse Large B Cell Lymphoma • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Rare Diseases • Thrombocytopenia

VENETOCLAX PLUS MITOXANTRONE HYDROCHLORIDE LIPOSOME AND AZACITIDINE (VMA) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE REAL-WORLD ANALYSIS (EHA 2026) - "Prospective studies are warranted to confirm these findings. ."

Real-world • Real-world evidence • Retrospective data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

EFFICACY AND SAFETY OF LIPOSOMAL MITOXANTRONE COMBINED WITH VENETOCLAX, AZACITIDINE, AND CHIDAMIDE (VACM) IN ACUTE MONOCYTIC LEUKEMIA (EHA 2026) - "Summary/Conclusion The VACM regimen demonstrates promising efficacy in AML-M5, achieving high CR and MRD negativity rates. These preliminary findings suggest that VACM may represent a viable therapeutic alternative for AML-M5 patients with poor response to standard Aza+Ven regimens, warranting validation in larger prospective studies."

Clinical • Acute Myelogenous Leukemia • Neutropenia